Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites.
The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 3.9M |
| Three Month Average Volume | 133.3M |
| High Low | |
| Fifty-Two Week High | 121.64 USD |
| Fifty-Two Week Low | 89.674 USD |
| Fifty-Two Week High Date | 08 Mar 2024 |
| Fifty-Two Week Low Date | 12 Oct 2023 |
| Price and Volume | |
| Current Price | 113.27 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.68% |
| Thirteen Week Relative Price Change | 3.56% |
| Twenty-Six Week Relative Price Change | -13.15% |
| Fifty-Two Week Relative Price Change | -12.15% |
| Year-to-Date Relative Price Change | -13.10% |
| Price Change | |
| One Day Price Change | 0.45% |
| Thirteen Week Price Change | 10.84% |
| Twenty-Six Week Price Change | -4.51% |
| Five Day Price Change | 0.51% |
| Fifty-Two Week Price Change | 10.08% |
| Year-to-Date Price Change | 2.91% |
| Month-to-Date Price Change | 6.92% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 22.26142 USD |
| Book Value Per Share (Most Recent Quarter) | 22.59788 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 3.52291 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.70315 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 5.72648 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 22.93253 USD |
| Revenue Per Share (Trailing Twelve Months) | 23.28849 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 2.04 USD |
| Dividend Per Share (Trailing Twelve Months) | 2.12 USD |
| Dividend Per Share (5 Year) | 1.688 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 3.27216 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 3.17808 USD |
| Normalized (Last Fiscal Year) | 3.42634 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 3.28908 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 3.1933 USD |
| Including Extraordinary Items (Last Fiscal Year) | 3.27216 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 3.17808 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.19762 USD |
| Cash Per Share (Most Recent Quarter) | 4.14909 USD |
| Cash Flow Per Share (Last Fiscal Year) | 5.12636 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 5.03455 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 1.12082 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 9 |
| Cash Flow Revenue (Trailing Twelve Months) | 5 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 15.98% |
| Pretax Margin (Last Fiscal Year) | 16.61% |
| Pretax Margin (5 Year) | 16.67% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 55.32% |
| Gross Margin (Trailing Twelve Months) | 55.43% |
| Gross Margin (5 Year) | 56.73% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 16.05% |
| Operating Margin (Trailing Twelve Months) | 15.82% |
| Operating Margin (5 Year) | 17.13% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 14.27% |
| Net Profit Margin (Trailing Twelve Months) | 13.65% |
| Net Profit Margin (5 Year) | 14.39% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 5.07% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -12.51% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 4.00% |
| Revenue Growth (3 Year) | 5.58% |
| Revenue Change (Trailing Twelve Months) | 1.24% |
| Revenue Per Share Growth | 5.83% |
| Revenue Growth (5 Year) | 5.04% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 9.57% |
| Total Debt (5 Year) | -5.59% |
| Dividends | |
| Dividend Growth (3 Year) | 12.31% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -5.36% |
| EPS Change (Trailing Twelve Months) | 8.06% |
| EPS Growth (3 Year) | 18.64% |
| EPS Growth (5 Year) | 9.13% |
| EBITDA | |
| EBITDA (5 Year) | 7.36% |
| EBITDA (5 Year Interim) | 6.66% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | 12.11% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 32 |
| Price to Tangible Book (Most Recent Quarter) | 24 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 131 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 101 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 7.5B |
| Net Debt (Last Fiscal Year) | 7.4B |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 36 |
| PE Normalized (Last Fiscal Year) | 33 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 33 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 58 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 22 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 36 |
| Dividends | |
| Dividend Yield (5 Year) | 1.52% |
| Dividend Yield | 1.94% |
| Current Dividend Yield | 1.87% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 5 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 35 |
| Long Term Debt to Equity (Most Recent Quarter) | 33 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 63.34% |
| Payout Ratio (Trailing Twelve Months) | 67.79% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 64 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 72 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 1.5B |
| Free Cash Flow (Trailing Twelve Months) | 2.0B |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 23 |
| Net Interest Coverage (Trailing Twelve Months) | 25 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 38 |
| Total Debt to Equity (Most Recent Quarter) | 38 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 7.75% |
| Return on Assets (Trailing Twelve Months) | 7.59% |
| Return on Assets (5 Year) | 7.72% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 15.20% |
| Return on Equity (Trailing Twelve Months) | 14.53% |
| Return on Equity (5 Year) | 16.28% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 9.71% |
| Return on Investment (Trailing Twelve Months) | 9.44% |
| Return on Investment (5 Year) | 9.39% |